
Opinion|Videos|April 7, 2025
A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk
Experts discuss an example illustrating the association between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD) risk and explore how this example can inform our understanding of Lp(a) and ASCVD risk on a population level.
Advertisement
Video content above is prompted by the following:
- Dr Wong, can you offer an example illustrating the association between Lp(a) levels and ASCVD risk?
- How might Dr Wong’s example inform how we think about Lp(a) and ASCVD risk on a population level?
Advertisement
Related to this article

Most patients with CLL/SLL who discontinued a first-line BTK inhibitor did not start second-line therapy, and older age was linked to worse outcomes.

Resmetirom real-world data at The Liver Meeting 2026 show 12-month gains in liver stiffness, fat, and enzymes among patients with MASH in 3 US data sets.

A study of 132 patients with AML given venetoclax-based therapy, 10 profiled by single-cell sequencing, linked immune features to treatment response.

This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.

Greater 340B activity—measured by county-level hospital child sites and contract pharmacy arrangements—was associated with significantly higher county-level total and out-of-pocket health care spending.

Clinicians at Population Health Roundtables shared obesity care innovations, from pharmacist-led models to same-day liver screening

The associate editor of Evidence-Based Oncology says the turnover that will follow this week's midterm election calls for renewed engagement from community oncology leaders with members of Congress, due to pressing reimbursement issues.
Advertisement
Advertisement
Trending on AJMC
1
EEOC Reportedly Plans to Narrow Pregnancy Accommodation Rules
2
How the GOLD 2026 Guidelines Updated COPD Diagnosis and Treatment
3
CF, Bronchiectasis Antimicrobial Resistance Varies Widely by Region
4
COPD Disease Stability Emerges as a Treatment Target in GOLD 2026
5


